About Auxogyn Intellectual Property
Our Intellectual Property Reflects Our Commitment to Innovation
Auxogyn is committed to developing innovative technologies that advance the field of reproductive health, and make a difference in the lives of families. Auxogyn invests significant resources to provide the best possible technologies for our customers and their patients. Our patents and other intellectual property are one aspect of that commitment.
Our initial intellectual property is licensed from Stanford University, and reflects ground-breaking work in understanding human embryo development described in part in a publication titled ’Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage,’ published in Nature Biotechnology, 2010.
Our first issued patent (United States Patent Number 7,963,906 (’906 Patent)) is licensed from Stanford University and covers predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn’s Eeva™ (early embryo viability assessment) System. Our second issued US patent, United States Patent Number 8,323,177, is also licensed exclusively to Auxogyn by Stanford University, and covers assessing embryo viability using predictive parameters. Auxogyn also has a broad portfolio of patents and patent applications worldwide related to reproductive health and Auxogyn’s technology (including additional patents which have been allowed).
Intellectual property in the medical technology field is subject to frequent challenges, both in courts and in front of patent offices throughout the world.
- In October 2011, the ’906 Patent became the subject of a challenge in front of both the United States Patent and Trademark Office (USPTO) and a US court.
- In October of 2012, the US Court dismissed the case challenging the ‘906 Patent.
- We remain confident that the ‘906 Patent will also overcome the challenge before the USPTO. The existing USPTO challenge does not inhibit Auxogyn’s ability to deliver novel technology to IVF clinicians around the world, nor does it prevent Auxogyn from enforcing the ‘906 Patent or the other valid, enforceable patents in its portfolio.
Auxogyn respects the intellectual property of others, and expects others to respect our intellectual property. Auxogyn takes pride in our innovative history and looks forward to providing many new, exciting technologies in the future. Please contact us at firstname.lastname@example.org if you have any questions regarding Auxogyn’s intellectual property.
CAUTION-Investigational Device. Limited by Federal (United States) law to investigational use.